Immutep Limited

NASDAQ:IMMP

Biotechnology

Healthcare
$0.37 +0.64%

+$0.00 today

Market cap
$55.01M
Beta
2.24
P/E (TTM)
-0.9
EPS (TTM)
-$0.06
52W Low $0.29High $3.53

Volume 3.10M

Average 13.46M

IMMP Interest Expense

Cost of servicing the company's debt during the period.

Immutep LimitedNASDAQ: IMMP

Interest Expense · Q2 FY2026 · quarter ended Dec 2025

Interest expense grows 65.8% year over year

Q2 FY2026 interest expense of A$18.94K rose 65.8% year over year. Over 3 fiscal years it compounded at -36.2% a year.

Context

  • Interest expense amounted to 0.5% of revenue in FY2025, down 0.3 pp from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
A$18.94K— QoQ
Last fiscal yearJun 2025
A$24.01K-21.5% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+65.8%——
1 year-21.5%——
3-year CAGR-36.2%——
5-year CAGR——
10-year CAGR——

Interest Expense history

AUD · from the income statement

Latest · FY2025
24.01K AUD
Year-over-year change
-21.5%
4-year CAGR
+25.0%

Interest Expense vs competitors

How IMMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -21.5% is the 4th highest of 8, against a peer median of -41.5%.
  • Interest expense amounts to 0.5% of revenue for IMMP, versus a peer median of 0.0%.
IMMP Competitors
Interest Expense for IMMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CADLCandel Therapeutics, Inc.LTM Mar 2026$3.38M USD+93.0%+7.5%—
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$3.05M USD———
CABACabaletta Bio, Inc.LTM Mar 2026$2.35M USD+125.1%——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$1.23M USD+270.1%——
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$908K USD-41.5%-22.9%—
MREOMereo BioPharma Group plcLTM Mar 2026$94.83K USD-92.3%-57.7%19.0%
IMMPImmutep LimitedFY2025A$24.01K AUD-21.5%-36.2%0.5%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$0 USD——0.0%
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
PRQRProQR Therapeutics N.V.LTM Mar 2026€0 EUR-100.0%-44.7%0.0%
EDITEditas Medicine, Inc.LTM Mar 2026-$1.14M USD-151.6%—3.0%
Peer median (excluding IMMP) —-41.5%-33.8%0.0%

Competitors are the stored peer set for IMMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue3.86M170.37K3.51M3.84M5.04M
Cost of Revenue17.24M2.06M2.06M41.55M61.41M
Gross Profit(13.37M)(1.89M)1.44M(37.7M)(56.37M)
Gross Margin-346.2%-1111.2%41.2%-981.4%-1117.6%
Research & Development17.24M31.34M28.79M41.55M61.41M
Selling, General & Admin6.28M7.21M14.08M8.85M8.64M
Operating Expenses18.3M32.55M44.94M50.4M70.06M
Depreciation & Amortization1.89M1.84M1.86M2.01M2.13M
EBITDA(17.77M)(31.87M)(39.57M)(44.54M)(62.88M)
EBITDA Margin-460.0%-18708.9%-1128.8%-1159.4%-1246.6%
Operating Income(31.68M)(33.94M)(77.69M)(88.1M)(126.42M)
Operating Margin-820.0%-19920.0%-2216.0%-2293.3%-2506.5%
Interest Income105.33K224.52K939K3.88M5.25M
Interest Expense9.83K92.43K20.4K30.59K24.01K
Other Income / Expenses1.77M1.63M37.79M45.39M64.99M
Income Before Tax(29.9M)(32.21M)(39.9M)(42.72M)(61.43M)
Pre-Tax Margin-774.1%-18906.5%-1138.0%-1111.9%-1218.0%
Income Tax Expense3334000
Net Income(29.9M)(32.21M)(39.9M)(42.72M)(61.43M)
Net Margin-774.1%-18906.5%-1138.0%-1111.9%-1218.0%
EPS (Basic)(0.49)(0.37)(0.44)(0.36)(0.42)
EPS (Diluted)(0.49)(0.37)(0.44)(0.36)(0.42)
Weighted Avg Shares60.43M86.23M90.06M119.99M145.58M
Weighted Avg Shares (Diluted)60.43M86.23M90.06M120.11M145.58M

Immutep Limited

NASDAQ:IMMP

Intrinsic Alpha fair value

Locked

Current Price

$0.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.